// App-Quantinova.ai

1349P : Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC in LUX-Lung (LL) 3, 6 and 7

Researchers

Presenter

  • L.Sequist

Principal Investigators

  • Y.-L.Wu

  • M.Schuler

  • T.Kato

  • J.C.-H.Yang

  • H.Tanaka

  • T.Hida

  • K.Park

  • S.Laurie

  • J.Bennouna

  • D.Moro Sibilot

  • A.Mrten

  • B.Peil

  • E.Ehrnrooth

  • N.Yamamoto

  • K.Nakagawa

Medical Centers

  • Massachusetts General Hosp Harvard Medcl School, Boston, MA

  • Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH) and Guangdong Academy of Medical Sciences, Guangzhou, China

  • West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany

  • Kanagawa Cancer Center, Yokohama, Japan

  • National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan

  • Niigata Cancer Center Hospital, Niigata City, Japan

  • Aichi Cancer Center Hospital, Nagoya, Japan

  • Department of Lung Cancer, Shanghai Chest Hospital, Shanghai, China

  • Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  • Division of Pharmacy, The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada

  • Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Nantes, France

  • Department of Medical Oncology, Centre Hospitalier Universitaire de Grenoble, Grenoble, France

  • Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim Am Rhein, Germany

  • TA Oncology, Boehringer Ingelheim, Denmark A/S, Copenhagen, Denmark

  • Second Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan

  • Department of Medical Oncology, Kyorin University School of Medicine, Tokyo, Japan

Locations

  • United States

  • China

  • Germany

  • Japan

  • Taiwan

  • Canada

  • France

  • Denmark

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Epidermal growth factor receptor

Drug/Treatment

  • Afatinib

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved